Navigation Links
Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress
Date:4/27/2011

DALLAS and NEW YORK, April 27, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes and RNAi, will attend this year's Oncology Nursing Society (ONS) Congress at the Boston Convention and Exhibition Center in Boston, MA.  The company's MuGard booth (#652) will be displayed in the Exhibition Hall of the convention center from Thursday, April 28th to Saturday, April 30th.

"We are excited to have a strong presence at the 36th Annual ONS Congress meeting," said Frank Jacobucci, VP of Sales and Marketing, Access Pharmaceuticals, Inc.  He continued, "ONS is well regarded as a premier event for educating oncology nurses on novel therapies and products used in cancer treatment regimens.  Oncology nurses remain on the front lines when treating patients for side effects of chemotherapy and radiation, especially when preventing and managing oral mucositis. Feedback on MuGard from oncology nurses has been overwhelmingly positive and we look forward to the meeting's ideal platform for broadening our already strong reach within the oncology nurse community."

About ONS:The Oncology Nursing Society (ONS) is a professional organization of over 35,000 registered nurses and other healthcare providers dedicated to excellence in patient care, education, research, and administration in oncology nursing. ONS members are a diverse group of professionals who represent a variety of professional roles, practice settings, and subspecialty practice areas. Registered nurses, including staff nurses, advanced practice nurses, case managers, educators, researchers, and consultants, and other healthcare professionals, benefit from membership. The Society offers useful information and opportunities for nurses at all levels, in all practice settings, and in all subspecialties. For more information on the Oncology Nursing Society and its 36th Annual Congress visit, http://www.ons.org/CNECentral/Conferences/Congress/2011.

About Access:Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.  

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: Company

Contact: Investor RelationsChristine Berni

Donald C. Weinberger/Diana Bittner (media)Director of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.

(212) 370-4500(212) 786-6208
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... NEW YORK , May 2, 2016 ... the EMR (Electronic Medical Records) market in a recent ... International sales, vendor switches, Increased physician usage, a growing market ... trends were noted in Kalorama,s report EMR ... The report marks Kalorama,s seventh complete study of the ...
(Date:5/2/2016)...  Celsion Corporation (NASDAQ: CLSN ), an ... the first cohort of patients in its Phase ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... the first three patients dosed, GEN-1 plus standard ...
(Date:4/29/2016)... April 29, 2016 Acquisition ... Sciences, Product Development Capabilities in North ... Base . Indegene ( http://www.indegene.com ... the acquisition of Skura Corporation,s life science business. ... adaptive sales enablement technology for life science organizations ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Dr. Poneh Ghasri, cosmetic ... treatments to both new and existing patients. Cosmetic dentistry allows patients to improve the ... have healthy smiles with some minor or more serious cosmetic flaws. These specials allow ...
(Date:5/3/2016)... ... May 03, 2016 , ... Celestix ... announced the new SecureAccess feature for its CelestixEdge solution. CelestixEdge is the ... enable organizations to get the DirectAccess user experience on unsupported DirectAccess clients ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... helps healthcare organizations, especially medium and small physician practices, to better grasp and ... unique step-by-step approach that guides practices on a well-defined, expert-created path to compliance. ...
(Date:5/2/2016)... ... May 03, 2016 , ... RNK Products, Inc. (RNK) ... software that enables the stethoscope stream to go over the video conferencing audio ... flagship PCP-USB stethoscope. , Remote auscultation involves two software elements on the PC: ...
(Date:5/2/2016)... ... May 02, 2016 , ... The ... Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused on research ... issue representing international (non-US) based authors, the third volume of PXJ continues to ...
Breaking Medicine News(10 mins):